The genetics and mechanisms of T cell acute lymphoblastic leukaemia

Nature Reviews Cancer

Volumn 16, Issue 8, 2016, Pages 494-507

  Belver, Laura ^a   Ferrando, Adolfo ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; INTERLEUKIN 7 RECEPTOR; JANUS KINASE; LYMPHOID ENHANCER FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NOTCH1 RECEPTOR; PROTEIN; PROTEIN KDM6A; PROTEIN MYB; PROTEIN SUZ12; RAS PROTEIN; RIBOSOME PROTEIN; STAT PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; WT1 PROTEIN; NOTCH1 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PROGNOSIS; CANCER RECURRENCE; GENE MUTATION; HUMAN; MOLECULAR MECHANICS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA; CELL CYCLE; DRUG RESISTANCE; GENETIC EPIGENESIS; GENETICS; PATHOLOGY;

CELL CYCLE; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; HUMANS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTOR, NOTCH1; RIBOSOMAL PROTEINS; SIGNAL TRANSDUCTION;

EID: 84979586915     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.63     Document Type: Review

References (203)

1. Hunger, S. P., & Mullighan, C. G. Acute lymphoblastic leukemia in children. N. Engl. J. Med. 373, 1541-1552 (2015
2. Litzow, M. R., & Ferrando, A. A. How I treat T cell acute lymphoblastic leukemia in adults. Blood 126, 833-841 (2015
3. Goldberg, J. M., et al. Childhood T cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J. Clin. Oncol. 21, 3616-3622 (2003
4. Weng, A. P., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004
5. Van Vlierberghe, P., et al. Prognostic relevance of integrated genetic profiling in adult T cell acute lymphoblastic leukemia. Blood 122, 74-82 (2013
6. Begley, C. G., et al. Chromosomal translocation in a human leukemic stem-cell line disrupts the T cell antigen receptor δ-chain diversity region and results in a previously unreported fusion transcript. Proc. Natl Acad. Sci. USA 86, 2031-2035 (1989
7. Xia, Y., et al. TAL2, a helix-loop-helix gene activated by the (7; 9)(q34; q32) translocation in human T cell leukemia. Proc. Natl Acad. Sci. USA 88, 11416-11420 (1991
8. Mellentin, J. D., Smith, S. D., & Cleary, M. L. lyl 1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 58, 77-83 (1989
9. Wang, J., et al. The t(14; 21)(q11.2; q22) chromosomal translocation associated with T cell acute lymphoblastic leukemia activates the BHLHB1 gene. Proc. Natl Acad. Sci. USA 97, 3497-3502 (2000
10. Royer-Pokora, B., Loos, U., & Ludwig, W. D. TTG 2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T cell leukaemia with the t(11; 14)(p13; q11). Oncogene 6, 1887-1893 (1991
11. McGuire, E. A., et al. The t(11; 14)(p15; q11) in a T cell acute lymphoblastic leukemia cell line activates multiple transcripts, including Ttg 1, a gene encoding a potential zinc finger protein. Mol. Cell. Biol. 9, 2124-2132 (1989
12. Kennedy, M. A., et al. HOX11, a homeobox-containing T cell oncogene on human chromosome 10q24. Proc. Natl Acad. Sci. USA 88, 8900-8904 (1991
13. Hatano, M., Roberts, C. W., Minden, M., Crist, W. M., & Korsmeyer, S. J. Deregulation of a homeobox gene, HOX11, by the t(10; 14) in T cell leukemia. Science 253, 79-82 (1991
14. Bernard, O. A., et al. A new recurrent and specific cryptic translocation, t(5; 14)(q35; q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia 15, 1495-1504 (2001
15. Homminga, I., et al. Integrated transcript and genome analyses reveal NKX2 1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 19, 484-497 (2011
16. Soulier, J., et al. HOXA genes are included in genetic and biologic networks defining human acute T cell leukemia (T ALL). Blood 106, 274-286 (2005
17. Erikson, J., et al. Deregulation of c myc by translocation of the alpha-locus of the T cell receptor in T cell leukemias. Science 232, 884-886 (1986
18. Ma, X., et al. Rise and fall of subclones from diagnosis to relapse in pediatric B acute lymphoblastic leukaemia. Nat. Commun. 6, 6604 (2015
19. Clappier, E., et al. The C MYB locus is involved in chromosomal translocation and genomic duplications in human T cell acute leukemia (T ALL), the translocation defining a new T ALL subtype in very young children. Blood 110, 1251-1261 (2007
20. Greaves, M. F., Janossy, G., Peto, J., & Kay, H. Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. Br. J. Haematol. 48, 179-197 (1981
21. Pui, C. H., Robison, L. L., & Look, A. T. Acute lymphoblastic leukaemia. Lancet 371, 1030-1043 (2008
22. Stock, W., et al. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer 119, 90-98 (2013
23. Sutton, R., et al. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br. J. Haematol. 168, 395-404 (2015
24. Ferrando, A. A., et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1, 75-87 (2002
25. Coustan-Smith, E., et al. Early T cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 10, 147-156 (2009
26. Van Vlierberghe, P., et al. ETV6 mutations in early immature human T cell leukemias. J. Exp. Med. 208, 2571-2579 (2011
27. Zhang, J., et al. The genetic basis of early T cell precursor acute lymphoblastic leukaemia. Nature 481, 157-163 (2012
28. Patrick, K., et al. Outcome for children and young people with early T cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br. J. Haematol. 166, 421-424 (2014
29. Niehues, T., et al. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T ALL with favorable outcome in the COALL studies. Leukemia 13, 614-617 (1999
30. Pitt, L. A., et al. CXCL12 producing vascular endothelial niches control acute T cell leukemia maintenance. Cancer Cell 27, 755-768 (2015
31. Passaro, D., et al. CXCR4 is required for leukemia-initiating cell activity in T cell acute lymphoblastic leukemia. Cancer Cell 27, 769-779 (2015
32. Dumortier, A., Wilson, A., MacDonald, H. R., & Radtke, F. Paradigms of notch signaling in mammals. Int. J. Hematol. 82, 277-284 (2005
33. Radtke, F., et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 10, 547-558 (1999
34. Ellisen, L. W., et al. TAN 1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66, 649-661 (1991
35. O'Neil, J., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ secretase inhibitors. J. Exp. Med. 204, 1813-1824 (2007
36. Thompson, B. J., et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 204, 1825-1835 (2007
37. Pear, W. S., et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J. Exp. Med. 183, 2283-2291 (1996
38. Chiang, M. Y., et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K ras-initiated leukemia. J. Clin. Invest. 118, 3181-3194 (2008
39. Li, N., et al. Cyclin C is a haploinsufficient tumour suppressor. Nat. Cell Biol. 16, 1080-1091 (2014
40. Xiong, H., et al. Characterization of two distinct lymphoproliferative diseases caused by ectopic expression of the Notch ligand DLL4 on T cells. PLoS ONE 8, e84841 (2013
41. Hodson, D. J., et al. Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia. Nat. Immunol. 11, 717-724 (2010
42. Palomero, T., et al. NOTCH1 directly regulates c MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl Acad. Sci. USA 103, 18261-18266 (2006
43. Weng, A. P., et al. c Myc is an important direct target of Notch1 in T cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 20, 2096-2109 (2006
44. Wang, H., et al. NOTCH1-RBPJ complexes drive target gene expression through dynamic interactions with superenhancers. Proc. Natl Acad. Sci. USA 111, 705-710 (2014
45. Herranz, D., et al. A NOTCH1 driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat. Med. 20, 1130-1137 (2014
46. Yashiro-Ohtani, Y., et al. Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia. Proc. Natl Acad. Sci. USA 111, E4946-E4953 (2014
47. Jarriault, S., et al. Signalling downstream of activated mammalian Notch. Nature 377, 355-358 (1995
48. Wendorff, A. A., et al. Hes1 is a critical but context-dependent mediator of canonical notch signaling in lymphocyte development and transformation. Immunity 33, 671-684 (2010
49. Palomero, T., Dominguez, M., & Ferrando, A. A. The role of the PTEN/AKT pathway in NOTCH1 induced leukemia. Cell Cycle 7, 965-970 (2008
50. Espinosa, L., et al. The Notch/Hes1 pathway sustains NF κB activation through CYLD repression in T cell leukemia. Cancer Cell 18, 268-281 (2010
51. Real, P. J., et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat. Med. 15, 50-58 (2009
52. Schnell, S. A., et al. Therapeutic targeting of HES1 transcriptional programs in T ALL. Blood 125, 2806-2814 (2015
53. Trimarchi, T., et al. Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell 158, 593-606 (2014
54. Hebert, J., Cayuela, J. M., Berkeley, J., & Sigaux, F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T-but not from B cell lineage acute lymphoblastic leukemias. Blood 84, 4038-4044 (1994
55. Kamijo, T., et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl Acad. Sci. USA 95, 8292-8297 (1998
56. Mullighan, C. G., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758-764 (2007
57. Remke, M., et al. High-resolution genomic profiling of childhood T ALL reveals frequent copy-number alterations affecting the TGF-β and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood 114, 1053-1062 (2009
58. Clappier, E., et al. Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T cell acute lymphoblastic leukemias. Leukemia 20, 82-86 (2006
59. Chen, Q., et al. Coding sequences of the tal 1 gene are disrupted by chromosome translocation in human T cell leukemia. J. Exp. Med. 172, 1403-1408 (1990
60. Bernard, O., et al. Two distinct mechanisms for the SCL gene activation in the t(1; 14) translocation of T cell leukemias. Genes Chromosomes Cancer 1, 194-208 (1990
61. Mansour, M. R., et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346, 1373-1377 (2014
62. Navarro, J. M., et al. Site-and allele-specific polycomb dysregulation in T cell leukaemia. Nat. Commun. 6, 6094 (2015
63. Kelliher, M. A., Seldin, D. C., & Leder, P. Tal 1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIα. EMBO J. 15, 5160-5166 (1996
64. Condorelli, G. L., et al. T cell-directed TAL 1 expression induces T cell malignancies in transgenic mice. Cancer Res. 56, 5113-5119 (1996
65. Sanda, T., et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell 22, 209-221 (2012
66. Kusy, S., et al. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1 expressing human T cell acute lymphoblastic leukemia. J. Exp. Med. 207, 2141-2156 (2010
67. Mansour, M. R., et al. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR 223 in human T cell acute lymphoblastic leukemia. J. Exp. Med. 210, 1545-1557 (2013
68. Kwiatkowski, N., et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511, 616-620 (2014
69. Homminga, I., et al. Characterization of a pediatric T cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements. Haematologica 97, 258-261 (2012
70. Van Vlierberghe, P., et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T cell acute lymphoblastic leukemia. Blood 108, 3520-3529 (2006
71. Van Vlierberghe, P., et al. Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T cell acute lymphoblastic leukemia. Leukemia 22, 1434-1437 (2008
72. Larson, R. C., et al. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J. 15, 1021-1027 (1996
73. Fisch, P., et al. T cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. Oncogene 7, 2389-2397 (1992
74. McGuire, E. A., Rintoul, C. E., Sclar, G. M., & Korsmeyer, S. J. Thymic overexpression of Ttg 1 in transgenic mice results in T cell acute lymphoblastic leukemia/lymphoma. Mol. Cell. Biol. 12, 4186-4196 (1992
75. Aplan, P. D., et al. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T cell malignancies in transgenic mice. EMBO J. 16, 2408-2419 (1997
76. Tremblay, M., et al. Modeling T cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. Genes Dev. 24, 1093-1105 (2010
77. Howe, S. J., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID X1 patients. J. Clin. Invest. 118, 3143-3150 (2008
78. Hacein-Bey-Abina, S., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID X1. J. Clin. Invest. 118, 3132-3142 (2008
79. Hacein-Bey-Abina, S., et al. LMO2 associated clonal T cell proliferation in two patients after gene therapy for SCID X1. Science 302, 415-419 (2003
80. Pearson, J. C., Lemons, D., & McGinnis, W. Modulating Hox gene functions during animal body patterning. Nat. Rev. Genet. 6, 893-904 (2005
81. Garcia-Fernandez, J. The genesis and evolution of homeobox gene clusters. Nat. Rev. Genet. 6, 881-892 (2005
82. Speleman, F., et al. A new recurrent inversion, inv(7) (p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T cell acute lymphoblastic leukemias. Leukemia 19, 358-366 (2005
83. Chervinsky, D. S., Sait, S. N., Nowak, N. J., Shows, T. B., & Aplan, P. D. Complex MLL rearrangement in a patient with T cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 14, 76-84 (1995
84. Rubnitz, J. E., et al. Molecular analysis of t(11; 19) breakpoints in childhood acute leukemias. Blood 87, 4804-4808 (1996
85. Tkachuk, D. C., Kohler, S., & Cleary, M. L. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 71, 691-700 (1992
86. Asnafi, V., et al. CALM AF10 is a common fusion transcript in T ALL and is specific to the TCRγδ lineage. Blood 102, 1000-1006 (2003
87. Van Vlierberghe, P., et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T cell acute lymphoblastic leukemia. Blood 111, 4668-4680 (2008
88. Dear, T. N., Sanchez-Garcia, I., & Rabbitts, T. H. The HOX11 gene encodes a DNA-binding nuclear transcription factor belonging to a distinct family of homeobox genes. Proc. Natl Acad. Sci. USA 90, 4431-4435 (1993
89. Ferrando, A. A., et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T cell acute lymphoblastic leukaemia. Lancet 363, 535-536 (2004
90. De Keersmaecker, K., et al. The TLX1 oncogene drives aneuploidy in T cell transformation. Nat. Med. 16, 1321-1327 (2010
91. Rakowski, L. A., Lehotzky, E. A., & Chiang, M. Y. Transient responses to NOTCH and TLX1/HOX11 inhibition in T cell acute lymphoblastic leukemia/lymphoma. PLoS ONE 6, e16761 (2011
92. Dadi, S., et al. TLX homeodomain oncogenes mediate T cell maturation arrest in T ALL via interaction with ETS1 and suppression of TCRα gene expression. Cancer Cell 21, 563-576 (2012
93. Ballerini, P., et al. HOX11L2 expression defines a clinical subtype of pediatric T ALL associated with poor prognosis. Blood 100, 991-997 (2002
94. Asnafi, V., et al. Impact of TCR status and genotype on outcome in adult T cell acute lymphoblastic leukemia: a LALA 94 study. Blood 105, 3072-3078 (2005
95. Della Gatta, G., et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T ALL. Nat. Med. 18, 436-440 (2012
96. Kleppe, M., et al. PTPN2 negatively regulates oncogenic JAK1 in T cell acute lymphoblastic leukemia. Blood 117, 7090-7098 (2011
97. Tosello, V., et al. WT1 mutations in T ALL. Blood 114, 1038-1045 (2009
98. Van Vlierberghe, P., et al. PHF6 mutations in T cell acute lymphoblastic leukemia. Nat. Genet. 42, 338-342 (2010
99. Graux, C., et al. Fusion of NUP214 to ABL1 on amplified episomes in T cell acute lymphoblastic leukemia. Nat. Genet. 36, 1084-1089 (2004
100. Przybylski, G. K., et al. The effect of a novel recombination between the homeobox gene NKX2 5 and the TRD locus in T cell acute lymphoblastic leukemia on activation of the NKX2 5 gene. Haematologica 91, 317-321 (2006
101. Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., & Dang, C. V. MYC, metabolism, and cancer. Cancer Discov. 5, 1024-1039 (2015
102. Dang, C. V. MYC on the path to cancer. Cell 149, 22-35 (2012
103. Dose, M., et al. c Myc mediates pre-TCR-induced proliferation but not developmental progression. Blood 108, 2669-2677 (2006
104. Mathieu-Mahul, D., et al. A t(8; 14)(q24; q11) translocation in a T cell leukemia (L1 ALL) with c myc and TcR-α chain locus rearrangements. Int. J. Cancer 38, 835-840 (1986
105. Sharma, V. M., et al. Notch1 contributes to mouse T cell leukemia by directly inducing the expression of c myc. Mol. Cell. Biol. 26, 8022-8031 (2006
106. Yada, M., et al. Phosphorylation-dependent degradation of c Myc is mediated by the F box protein Fbw7. EMBO J. 23, 2116-2125 (2004
107. Welcker, M., et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c Myc protein degradation. Proc. Natl Acad. Sci. USA 101, 9085-9090 (2004
108. King, B., et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 153, 1552-1566 (2013
109. Roderick, J. E., et al. c Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T ALL cells. Blood 123, 1040-1050 (2014
110. Loosveld, M., et al. Therapeutic targeting of c Myc in T cell acute lymphoblastic leukemia, T ALL. Oncotarget 5, 3168-3172 (2014
111. Lahortiga, I., et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat. Genet. 39, 593-595 (2007
112. O'Neil, J., et al. Alu elements mediate MYB gene tandem duplication in human T ALL. J. Exp. Med. 204, 3059-3066 (2007
113. Mets, E., et al. MicroRNA 193b 3p acts as a tumor suppressor by targeting the MYB oncogene in T cell acute lymphoblastic leukemia. Leukemia 29, 798-806 (2015
114. Sanghvi, V. R., et al. Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia. Sci. Signal. 7, ra111 (2014
115. Wang, L. C., et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev. 12, 2392-2402 (1998
116. Hock, H., et al. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev. 18, 2336-2341 (2004
117. Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84, 321-330 (1996
118. Cai, Z., et al. Haploinsufficiency of AML1 affects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo. Immunity 13, 423-431 (2000
119. Growney, J. D., et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 106, 494-504 (2005
120. Song, W. J., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat. Genet. 23, 166-175 (1999
121. Owen, C. J., et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 112, 4639-4645 (2008
122. Ting, C. N., Olson, M. C., Barton, K. P., & Leiden, J. M. Transcription factor GATA 3 is required for development of the T cell lineage. Nature 384, 474-478 (1996
123. Zahirieh, A., et al. Functional analysis of a novel GATA3 mutation in a family with the hypoparathyroidism, deafness, and renal dysplasia syndrome. J. Clin. Endocrinol. Metab. 90, 2445-2450 (2005
124. Wakabayashi, Y., et al. Homozygous deletions and point mutations of the Rit1/Bcl11b gene in γ-ray induced mouse thymic lymphomas. Biochem. Biophys. Res. Commun. 301, 598-603 (2003
125. Li, L., Leid, M., & Rothenberg, E. V. An early T cell lineage commitment checkpoint dependent on the transcription factor Bcl11b. Science 329, 89-93 (2010
126. Wakabayashi, Y., et al. Bcl11b is required for differentiation and survival of αβT lymphocytes. Nat. Immunol. 4, 533-539 (2003
127. Gutierrez, A., et al. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T cell acute lymphoblastic leukemia. Blood 118, 4169-4173 (2011
128. Brantjes, H., Roose, J., van de Wetering, M., & Clevers, H. All Tcf HMG box transcription factors interact with Groucho-related co repressors. Nucleic Acids Res. 29, 1410-1419 (2001
129. Gutierrez, A., et al. Inactivation of LEF1 in T cell acute lymphoblastic leukemia. Blood 115, 2845-2851 (2010
130. Ellisen, L. W., Carlesso, N., Cheng, T., Scadden, D. T., & Haber, D. A. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 20, 1897-1909 (2001
131. Van Vlierberghe, P., et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia 25, 130-134 (2011
132. Welch, J. S., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278 (2012
133. Lower, K. M., et al. Mutations in PHF6 are associated with Borjeson-Forssman-Lehmann syndrome. Nat. Genet. 32, 661-665 (2002
134. Chao, M. M., et al. T cell acute lymphoblastic leukemia in association with Borjeson-Forssman-Lehmann syndrome due to a mutation in PHF6. Pediatr. Blood Cancer 55, 722-724 (2010
135. Todd, M. A., & Picketts, D. J. PHF6 interacts with the nucleosome remodeling and deacetylation (NuRD) complex. J. Proteome Res. 11, 4326-4337 (2012
136. Wang, J., et al. PHF6 regulates cell cycle progression by suppressing ribosomal RNA synthesis. J. Biol. Chem. 288, 3174-3183 (2013
137. Zhang, C., et al. The X linked intellectual disability protein PHF6 associates with the PAF1 complex and regulates neuronal migration in the mammalian brain. Neuron 78, 986-993 (2013
138. Liu, Z., et al. Structural basis of plant homeodomain finger 6 (PHF6) recognition by the retinoblastoma binding protein 4 (RBBP4) component of the nucleosome remodeling and deacetylase (NuRD) complex. J. Biol. Chem. 290, 6630-6638 (2015
139. Cao, R., et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039-1043 (2002
140. Ntziachristos, P., et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 18, 298-301 (2012
141. Ntziachristos, P., et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514, 513-517 (2014
142. Lan, F., et al. A histone H3 lysine 27 demethylase regulates animal posterior development. Nature 449, 689-694 (2007
143. Van der Meulen, J., et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T cell acute lymphoblastic leukemia. Blood 125, 13-21 (2015
144. Webb, L. M., Vigorito, E., Wymann, M. P., Hirsch, E., & Turner, M. Cutting edge: T cell development requires the combined activities of the p110γ and p110δ catalytic isoforms of phosphatidylinositol 3 kinase. J. Immunol. 175, 2783-2787 (2005
145. Palomero, T., et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T cell leukemia. Nat. Med. 13, 1203-1210 (2007
146. Mendes, R. D., et al. PTEN microdeletions in T cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events. Blood 124, 567-578 (2014
147. Suzuki, A., et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8, 1169-1178 (1998
148. Mao, C., et al. Unequal contribution of Akt isoforms in the double-negative to double-positive thymocyte transition. J. Immunol. 178, 5443-5453 (2007
149. Kalaitzidis, D., et al. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell 11, 429-439 (2012
150. Gutierrez, A., et al. High frequency of PTEN, PI3K, and AKT abnormalities in T cell acute lymphoblastic leukemia. Blood 114, 647-650 (2009
151. Karrman, K., et al. The t(X; 7)(q22; q34) in paediatric T cell acute lymphoblastic leukaemia results in overexpression of the insulin receptor substrate 4 gene through illegitimate recombination with the T cell receptor β locus. Br. J. Haematol. 144, 546-551 (2009
152. Mazzucchelli, R., & Durum, S. K. Interleukin 7 receptor expression: intelligent design. Nat. Rev. Immunol. 7, 144-154 (2007
153. Lacronique, V., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309-1312 (1997
154. Shochat, C., et al. Gain of function mutations in interleukin 7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J. Exp. Med. 208, 901-908 (2011
155. Zenatti, P. P., et al. Oncogenic IL7R gain of function mutations in childhood T cell acute lymphoblastic leukemia. Nat. Genet. 43, 932-939 (2011
156. Yokoyama, K., et al. In vivo leukemogenic potential of an interleukin 7 receptor α chain mutant in hematopoietic stem and progenitor cells. Blood 122, 4259-4263 (2013
157. Treanor, L. M., et al. Interleukin 7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J. Exp. Med. 211, 701-713 (2014
158. Maude, S. L., et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T cell precursor (ETP) acute lymphoblastic leukemia. Blood 125, 1759-1767 (2015
159. Tremblay, C. S., et al. Loss of function mutations of Dynamin 2 promote T ALL by enhancing IL 7 signalling. Leukemia http://dx.doi.org/10.1038/leu.2016.100 (2016
160. Vainchenker, W., & Constantinescu, S. N. JAK/STAT signaling in hematological malignancies. Oncogene 32, 2601-2613 (2013
161. De Keersmaecker, K., et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T cell acute lymphoblastic leukemia. Nat. Genet. 45, 186-190 (2013
162. Flex, E., et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J. Exp. Med. 205, 751-758 (2008
163. Degryse, S., et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T cell acute lymphoblastic leukemia in a mouse model. Blood 124, 3092-3100 (2014
164. Kontro, M., et al. Novel activating STAT5B mutations as putative drivers of T cell acute lymphoblastic leukemia. Leukemia 28, 1738-1742 (2014
165. Bandapalli, O. R., et al. The activating STAT5B N642H mutation is a common abnormality in pediatric T cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica 99, e188-e192 (2014
166. Perez-Garcia, A., et al. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood 122, 2425-2432 (2013
167. Balgobind, B. V., et al. Leukemia-associated NF1 inactivation in patients with pediatric T ALL and AML lacking evidence for neurofibromatosis. Blood 111, 4322-4328 (2008
168. Kindler, T., et al. K-RasG12D-induced T cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to γ-secretase inhibitors. Blood 112, 3373-3382 (2008
169. Ruggero, D., & Pandolfi, P. P. Does the ribosome translate cancer? Nat. Rev. Cancer 3, 179-192 (2003
170. van Riggelen, J., Yetil, A., & Felsher, D. W. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat. Rev. Cancer 10, 301-309 (2010
171. Hsieh, A. C., Truitt, M. L., & Ruggero, D. Oncogenic AKTivation of translation as a therapeutic target. Br. J. Cancer 105, 329-336 (2011
172. Wolfe, A. L., et al. RNA G quadruplexes cause eIF4A dependent oncogene translation in cancer. Nature 513, 65-70 (2014
173. Tzoneva, G., et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat. Med. 19, 368-371 (2013
174. Piovan, E., et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 24, 766-776 (2013
175. Bandapalli, O. R., et al. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T cell acute lymphoblastic leukemia. Haematologica 98, 928-936 (2013
176. Wei, G., et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10, 331-342 (2006
177. Pui, C. H., & Evans, W. E. A 50 year journey to cure childhood acute lymphoblastic leukemia. Semin. Hematol. 50, 185-196 (2013
178. Bhojwani, D., & Pui, C. H. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 14, e205-e217 (2013
179. Burke, M. J., et al. Transplant outcomes for children with T cell acute lymphoblastic leukemia in second remission: a report from the Center for International Blood and Marrow Transplant Research. Biol. Blood Marrow Transplant 21, 2154-2159 (2015
180. Goldstone, A. H., et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111, 1827-1833 (2008
181. Kozlowski, P., et al. High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden. Eur. J. Haematol. 92, 377-381 (2014
182. Meyer, J. A., et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat. Genet. 45, 290-294 (2013
183. Brouwer, C., et al. Role of 5′ nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6 mercaptopurine treatment. Clin. Chim. Acta 361, 195-103 (2005
184. Hunsucker, S. A., Mitchell, B. S., & Spychala, J. The 5′ nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol. Ther. 107, 1-30 (2005
185. Kunz, J. B., et al. Pediatric T cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. Haematologica 100, 1442-1450 (2015
186. Paganin, M., & Ferrando, A. Molecular pathogenesis and targeted therapies for NOTCH1 induced T cell acute lymphoblastic leukemia. Blood Rev. 25, 83-90 (2011
187. Quintas-Cardama, A., et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1 positive T cell malignancies. Leukemia 22, 1117-1124 (2008
188. Chiarini, F., et al. Activity of the novel dual phosphatidylinositol 3 kinase/mammalian target of rapamycin inhibitor NVP BEZ235 against T cell acute lymphoblastic leukemia. Cancer Res. 70, 8097-8107 (2010
189. Peirs, S., et al. ABT 199 mediated inhibition of BCL 2 as a novel therapeutic strategy in T cell acute lymphoblastic leukemia. Blood 124, 3738-3747 (2014
190. Chonghaile, T. N., et al. Maturation stage of T cell acute lymphoblastic leukemia determines BCL 2 versus BCL XL dependence and sensitivity to ABT 199. Cancer Discov. 4, 1074-1087 (2014
191. Sawai, C. M., et al. Therapeutic targeting of the cyclin D3: CDK4/6 complex in T cell leukemia. Cancer Cell 22, 452-465 (2012
192. Bash, R. O., et al. Does activation of the TAL1 gene occur in a majority of patients with T cell acute lymphoblastic leukemia? A Pediatric Oncology Group study. Blood 86, 666-676 (1995
193. Heerema, N. A., et al. Frequency and clinical significance of cytogenetic abnormalities in pediatric T lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group. J. Clin. Oncol. 16, 1270-1278 (1998
194. Le Noir, S., et al. Extensive molecular mapping of TCRα/δ-and TCRβ-involved chromosomal translocations reveals distinct mechanisms of oncogene activation in T ALL. Blood 120, 3298-3309 (2012
195. Ferrando, A. A., et al. Gene expression signatures in MLL-rearranged T lineage and B precursor acute leukemias: dominance of HOX dysregulation. Blood 102, 262-268 (2003
196. Goossens, S., et al. ZEB2 drives immature T cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL 7 receptor signalling. Nat. Commun. 6, 5794 (2015
197. Lange, B. J., et al. Pediatric leukemia/lymphoma with t(8; 14)(q24; q11). Leukemia 6, 613-618 (1992
198. Grossmann, V., et al. The molecular profile of adult T cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T ALL. Genes Chromosomes Cancer 52, 410-422 (2013
199. De Keersmaecker, K., et al. Fusion of EML1 to ABL1 in T cell acute lymphoblastic leukemia with cryptic t(9; 14)(q34; q32). Blood 105, 4849-4852 (2005
200. Van Limbergen, H., et al. Molecular cytogenetic and clinical findings in ETV6/ABL1 positive leukemia. Genes Chromosomes Cancer 30, 274-282 (2001
201. Bar-Eli, M., Ahuja, H., Foti, A., & Cline, M. J. N RAS mutations in T cell acute lymphocytic leukaemia: analysis by direct sequencing detects a novel mutation. Br. J. Haematol. 72, 36-39 (1989
202. Asnafi, V., et al. JAK1 mutations are not frequent events in adult T ALL: a GRAALL study. Br. J. Haematol. 148, 178-179 (2010
203. Paietta, E., et al. Activating FLT3 mutations in CD117/KIT+ T cell acute lymphoblastic leukemias. Blood 104, 558-560 (2004